<DOC>
	<DOCNO>NCT02084719</DOCNO>
	<brief_summary>Rapid test increasingly use medical practice , notably screen HIV . Their use associate faster linkage care lower rate loss follow . Rapid test also well accepted patient clinician . No rapid test currently approve Canada screen hepatitis C. Hepatitis C diagnosis do base blood test screen algorithm may require 3 visit clarify hepatitis C status . The Oraquick HCV test rapid test do blood saliva replace first step regular screen algorithm . With test initial screen confirmation test do one visit . The primary endpoint pilot-project evaluate clinical characteristic Oracquick HCV ( sensitivity , specificity , positive negative predictive value ) compare standard screen algorithm population active ex-users inject drug . The project also intend evaluate rapid test reduce rate loss follow increase linkage hepatitis C specialize care . This last endpoint evaluate phone call follow 6 month screen . One hundred fifty patient include . Half test standard algorithm Oraquick HCV test ( group A ) half tested standard algorithm . Results group A use determine clinical characteristic Oraquick HCV . Results group A B used evaluate rate loss follow , cost avoid use rapid test linkage care infected patient .</brief_summary>
	<brief_title>Comparison OraQuick HCV Rapid Antibody Test Standard Serologic Screening Hepatitis C : Validity , Acceptability Impact Linkage Care</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<criteria>Indication hepatitis C screen Active exinjection drug user Known hepatitis C infection Unknown HIV status patient refuse HIV test</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>